Nurse resources

Below are resources for nurses—as well as tools to use with their patients—to better understand Somatuline® Depot (lanreotide) Injection 120 mg as a treatment option for gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

Injection Training Video

Somatuline Depot utilizes a low-volume (0.5 mL) injection that is delivered through the deep subcutaneous route.1 Click the image to watch now.

FAQ Videos

Narrated by Pamela Ryan, BSN, RN, of the Oschner Medical Center, these videos answer the most common questions nurses may have about Somatuline Depot. Click the image to watch now.

Tap on a topic below to view a video
  1. What is the approved indication for Somatuline Depot Injection and does it carry a contraindication?
  2. What is Somatuline Depot? How is it different from other somatostatin analogs (SSAs)?
  3. Which patients could benefit from treatment with Somatuline Depot?
  4. What key information about the pivotal clinical trial (CLARINET) should we know?
  5. In the pivotal Phase III CLARINET trial, what were the reported side effects of Somatuline Depot?
  6. What are the administration features of Somatuline Depot?
  7. What would happen if I accidentally injected Somatuline Depot intramuscularly into a patient?
  8. Where can patients prescribed Somatuline Depot find information on insurance coverage and financial support?
  9. What is the Important Safety Information for Somatuline Depot?

Somatuline Depot Patient Brochure

Specifically created for patients and caregivers to receive information about Somatuline Depot and IPSEN CARES™. Click image to view and download.

Treatment Journal for Patients

This guide allows patients to keep track of important information about their disease and their treatment plan. Click image to view and download.

IPSEN CARES Program Overview

This piece will help you highlight the benefits of IPSEN CARES to your patients and their caregivers. Click image to view and download.

IPSEN CARES Copay Assistance Program

This piece contains information you need to discuss IPSEN CARES copay savings with your eligible patients. Click image to view and download.


Somatuline® Depot (lanreotide) Injection 120 mg is indicated for the treatment of adult patients with unresectable, well- or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to improve progression-free survival.

Important Safety Information

Somatuline Depot is contraindicated in patients with hypersensitivity to lanreotide. Allergic reactions (including angioedema and anaphylaxis) have been reported following administration of lanreotide.

Warnings and Precautions:
  • Cholelithiasis and Gallbladder Sludge: Somatuline Depot may reduce gallbladder motility and lead to gallstone formation. Periodic monitoring may be needed.
  • Hypoglycemia or Hyperglycemia: Pharmacological studies show that Somatuline Depot, like somatostatin and other somatostatin analogs, inhibits the secretion of insulin and glucagon. Blood glucose levels should be monitored when Somatuline Depot treatment is initiated, or when the dose is altered, and antidiabetic treatment should be adjusted accordingly.
  • Cardiac Abnormalities: Somatuline Depot may decrease heart rate. In 81 patients with baseline heart rates of ≥60 beats per minute (bpm) treated with Somatuline Depot in the GEP-NETs clinical trial, the incidence of heart rate <60 bpm was 23% (19/81) with Somatuline Depot vs 16% (15/94) with placebo; 10 patients (12%) had documented heart rates <60 bpm on more than one visit. The incidence of documented episodes of heart rate <50 bpm or bradycardia reported as an adverse event was 1% in each treatment group. Initiate appropriate medical management in patients who develop symptomatic bradycardia. In patients without underlying cardiac disease, Somatuline Depot may lead to a decrease in heart rate without necessarily reaching the threshold of bradycardia. In patients suffering from cardiac disorders prior to treatment, sinus bradycardia may occur. Care should be taken when initiating treatment in patients with bradycardia.
  • Drug Interactions: The pharmacological gastrointestinal effects of Somatuline Depot may reduce the intestinal absorption of concomitant drugs. Concomitant administration of Somatuline Depot may decrease the relative bioavailability of cyclosporine and may necessitate the adjustment of cyclosporine dose to maintain therapeutic levels.
Adverse Reactions:

In the GEP-NET pivotal trial, the most common adverse reactions (incidence of >10% and more common than placebo) in patients treated with Somatuline Depot vs placebo were abdominal pain (34% vs 24%), musculoskeletal pain (19% vs 13%), vomiting (19% vs 9%), headache (16% vs 11%), injection site reaction (15% vs 7%), hyperglycemia (14% vs 5%), hypertension (14% vs 5%), and cholelithiasis (14% vs 7%).

You may report suspected adverse reactions to FDA at 1-800-FDA-1088 or to Ipsen Biopharmaceuticals, Inc. at 1-888-980-2889.

Please click here for full Prescribing Information and for full Important Safety Information.

Reference: 1. Somatuline Depot (lanreotide) Injection [Prescribing Information]. Basking Ridge, NJ: Ipsen Biopharmaceuticals, Inc; December 2014.